• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Antibacterial activity is exhibited by monocyclic β-lactam antibiotics having in the 1-position an -O-SO3H activating group and in the 3-position an acylamino group of the formula wherein R3 and R4 are each independently hydrogen or alkyl.
    公开号:SU1517762A3
    申请号:SU874028791
    申请日:1987-01-05
    公开日:1989-10-23
    发明作者:Эдвард Сандин Джозеф
    申请人:Е.Р.Сквибб Энд Санз., Инк (Фирма)；
    IPC主号:
    专利说明:

    one
    (21) A0287 P / 23-04
    (22) 01/05/87
    (31) 816475
    (32) 01/06/86
    (33) US
    (46) 23,10.89. Lul. No. 39
    (71) E.R.SkviAb & Sons, R1nk. (US)
    (72) Joseph Edward Sandin (US)
    (53) 547.718789.07Г088.8)
    (56) US Patent No. 4,144,333, cl. 424-244, published. 1979
    (54) METHOD FOR GETTING MONOSULA
    (57) The invention relates to heterocyclic substances and, in particular, to the preparation of compounds of the general formula (I):
    NC (NHj) - S - CH (; - SC N - - O - C (CH7.) - C (0) ph, where K is C (0) - - im-CH-CR Rj-NY is c 0; Y-05 (0) is OH; R, and R is lower alkyl or R, + R - (CH ,,) - which, as antibacterial agents, can be used in medicine. The purpose of the invention is to create new more active substances of the indicated class. Synthesis is carried out by removing from carboxyl-protected (diphenylmethylim, phenylmethyl or t-butyl) the compounds of formula (I) of the indicated ester group. New substances have low toxicity and are active against urinary tract infections, respiratory infections, i.e. against gram-positive and gr n- negative bacteria. Table 1.
     (ABOUT
    This invention relates to a process for the production of novel chemical biologically active compounds, specifically monosulfoctam derivatives, exhibiting antibacterial activity. This property suggests the possibility of using these compounds in medicine.
    The purpose of the invention is to obtain new monosulfocar derivatives with improved antibacterial activity in a number of monocyclic R-lactam antibiotics.
    Example 1. (±) -И-2- 1- - (2-Amino-4-thiazolyl) -2- 4,4-dime-TI.P-2-OXO-1 - (sul1 fax) -3-azetidi - Nile amino -2-oxo-ethyl-11-dimerp3-sho-hydroxy-2-acrylic acid.
    A. 2- 1,3-dioxo-2H-isoindole-2- (yl) oxy-2-acrylic acid.
    A solution of complex 2 - {((, 3-dioxo-2H-isoindol--2-yl) oxy | -2-acrylic acid (1.75 g, 5.7 mmol) in methylene chloride; De (10 ml ) and anisole (10 ml) is formed by batt trifluoroacetic acid (5 ml). After stirring overnight at room temperature, toluene was added and the reaction mixture was concentrated in vacuo. The residue was triturated twice using hexane to give 1.54 g of the title compound.
    B, Diphenylmethyl ester- -2 (, 3-dioxo-2H-isoindol-2-yl) oxa-2-acrylic acid,
    2- (1, 3-dioxo-2H-iso1-SCHOL-2-yl) hydroxy-2-acrylic acid (1.54 g, 4.8 mmol) is dissolved in 25 mp of acetonitrile and rastsp is added dropwise

    to

    O4
    ten
    31517762
    Thief diphenyldiazomethane 1.17 g, 5.9 NtMonb / 50 ml acetonitrile). After adding about 1.1 g-equiv of diphenyldiazomethane, thin layer chromatography does not show any starting material that would remain in the mixture. Excess diphenyl diazomethane is cleaved by the addition of a small amount of acetic acid. The reaction solution is concentrated to a residue, dissolved in ethyl acetate, washed successively with 1N. sodium bicarbonate solution and brine, dried in the presence of anhydrous magnesium sulphate and evaporated to a solid. After powdering with hexane, 1.9 g of the title compound are obtained. 2n
    C. 2-Amino- (C- - (diphenylmethoxy) carbonyl vinyl hydroxy-imino -4-thiazoleacetic acid.
    To a solution of complex diphenylmethyl ester of 2- (1, 3-DIOXO-2H-IZOIN- 25 dol-2-yl) oxy -2-acrylic acid (0.8 g, 2 mmol) in 50 ml of methylene chloride under argon hydrazine hydrate (100 mg, 2 mmol in 1 ml of absolute ethanol) is added at 0 ° C. The reaction mixture is slowly heated from 0 ° C to room temperature over 1 hour and then stirred at room temperature for 2 hours. The white precipitate is filtered off, the solution is diluted with diethyl ether and filtered again. The volatile components are then removed from the filtrate to give 2-aminooxy-2-acrylic acid as a residue. 2-Aminoxy-2-acrylic acid is then dissolved in ethanol (6 ml) and water (4 ml), after which 2-amino-azole-4-glyoxylic acid (0.31 g, 1.8%) is added to the solution. mmol). After stirring at room temperature for 17 hours, thin layer chromatography shows that the reaction is incomplete. Additional ethanol and water are added, and non--50 is added to solubilize the reactants.
    significant amount of dimethylformamide. After stirring for 72 hours, thin layer chromatography does not show the remaining 2-aminooxy-2-acrylic acid. Evaporation results in a crude title compound that is chromatographed on an HP20 column.
    thirty
    35
    40
    45
    ale in pr water for
    - (am
    Nli gi su -1 di re pr 13 si fu kra on Neut aren’t sous up to 13s of th
    from $ to lp station (1 ka ma och ov r on pi
    nor 20 9,
    0
    g p
    50
    55
    0
    five
    0
    five
    gradient eluted with acetonitrile / water (0-80%). The fractions containing the product are concentrated to remove acetonitrile. Filtration of the resulting aqueous suspension provided the title compound as a precipitate. After drying in vacuo overnight, 167 mg of the title compound were obtained.
    D.Y- (t-Butyloxycarbonyl) -H - - (phenylmethoxy) -B, L-3-oxyaline-amide.
    A solution of 24.84 g (106.6 mmol) of N-butyloxycarbonyl-D, L-3-oxivaline and 16.33 g (106.6 mmol) of oxybenzothiazole monohydrate in 500 ml of dry tetrahydrofuran is cooled to -10 ° C and added 22 g (106.6 mmol) of dicyclohexylcarbodiimide. The mixture was stirred under nitrogen for 1 hour at O (. Thereafter, a solution of 13.13 g (106.6 mmol) of 0-benzylhydroxylamine in 250 ml of dry tetrahyro furan was added over 15 minutes to the activated ester mixture and the mixture is stirred under nitrogen for 1 h at 0 ° C. The insoluble material is filtered off and the filtrate is evaporated in vacuo to a foam. The foam is extracted with ethyl acetate and the insoluble material is removed by filtration. The organic phase is dried (sodium sulfate) and evaporated to a syrup, which is crystallized from 130 ml of simple isop opilovogo ether to give 24.7 g of the title compound;.. m.p. 76-78 ° C.
    E. Pyridinium salt of H- (t-butyl- with $ xycarboxy 1) (phenylmethoxy) -0, bz- (sulfooxy) valinamide.
    Dry pyridine (8.08 ml, 0.10 mol) is placed in a 500 ml round-bottomed flask and cooled to -10 ° C under nitrogen. Trimethylsilyl chlorosulfonate (15.6 ml, 0.10 mol) is added dropwise (vigorous stirring with a magnetic stirrer), after which the very thick reaction mixture (due to precipitation of the product) is stirred for 0.5 h at 0 ° C. Chlorotrimethylsilane is removed in vacuo to give 15 g of the pyridine-sulfur trioxide complex compound.
    N- (t-butyloxycarbonyl) -N - (phenylmethoxy) -0, L-3-oxalivalamide (16.92 g, 50 mmol) is dissolved in 200 ml of dry pyridine and 9.87 g (62.5 mmol) complex
    51
    pyridine compounds - sulfuryl trioxide, the mixture is stirred at a liter: yutog. within 2 hours. Add another portion (790 mg, 5 mmol) of the pyridine-sulfur trioxide complex and stirring continue for another 1 hour. Reactor off of the mixture is stripped in vacuum E oil. The oil is distilled off in 3 times under vacuum from acetonitrile with the preparation of the product, the pointer and the backwash, and the like 1) The withdrawal is taken as quantitative.
    G. (i -) - 3- (t-butyloxycarbonyl) amipo-4, 4-dimethyl-1 - (|}) epilmethoxy) - -2-azetidiponO
    A flask containing crude pyridium) salt of N- (t-butyloxycnrbbo-Hi-ui) -N - (f, nilmptoxy) -0, b-3- (sulbox) - gsg; ling, 1mida (approx. ptelip 50 mmol), noMGitiaioT in a panna with ice and with vigorous stirring, add 400 L of ethyl cepate, then a solution of 42.8 g (0.3) mol) of potassium carbonate in 90 M: I water. The resulting mixture — chipergio pspemetuyut with reverse HOLPDIL1-NPKOM for 2 h under the ZO-T (1M. Reaction1; the cooling mixture; t, ay to the room temperature and phase from the. Water phase of PCS Gragutotox 2 X 200 ml , etat and all organic phases are about 7: (; they are dried, dried (s; sodium ulfate) and evaporated in a vacuum. The oil is taken in 40% ethyl acetate / hexane (125 ml) and quickly filtered through ml of pillow (10 cm) Mallincrodt Silicon AR CC-7, use 3 to 4 liters of 40% -iroii ethyl acetate / hexane o mixture The filtrate is evaporated in vacuo to a solid residue (12.2 g). Crystallized from 50 ml And zopropyl ether gives 7.15 g of the title compound; mp; 110 C.
    G. (±) -3-- (t-butyloxycarbonip (ampno -1-oxy-4,4-dimethyl-2-azetidinone,
    (i) -3 (t-butyloxycarbonyl) ami-, 4-dimoш1-1- (phenylmethoxy) -2-β-azetidinone (8.07 g, 25 mmol) is hydrogenated at atmospheric pressure and ambient temperature with 40 ml of methanol with 0.5 g - 10% palladium carbon as catalyst B for 2 hours. The reaction mixture is filtered through a Celite pad and the filtrate is concentrated to give 5.78 g of the title compound as a solid stat.
    77626
    N. Tetrabutylammonium salt of (±) -3-С (t-butyloxycarbonyl) amino-4, 4-dimethyl-2-oxo-1-azetidipyl sulfate.
    A solution of chloroacetic acid (12.27 g, 0.105 mol) in 210 ml of dichloromethane at -40 ° C is treated dropwise with 20.5 g
    Q (0.26 mol) of pyridine for
    10 min. The mixture is stirred for 10 minutes at OG, and 10 minutes at 25 ° H. Inspection of (t) -3- (t-butyloxycarbonyl) ampo-1-hydroxy-4,4-dimethyl-2-azetidinone in
    5 20 ml of dichloromethane are added to the mixture, which is then stirred for 3.5 hours. The nearly homogeneous solution is then treated with 250 liters of water and 17 g (0.05 mol) of tetrabutylammonium sulphate. Dares, horses are unmixed and the organic layer is separated and dried in the presence of sodium sutir. Evaporation under vacuum will give a foam, which is purified by stretching i;
    5 with ethyl acetate, remove the insoluble substances, and evaporate to the title compound as a foam, 30 g.
    I. () -3-lmino-4,4-dimethyl-2-ok Q co-1-azetidinyl sulfate.
    A solution of tetrabutylammonium salt -, (1:) - 3- (t-butyloxycarbo} Chl) pmpno | - -4, 4-dimethyl-2-oxo-1 -azetidin.i; - sulfate (30 g, 0.05 mol) B 125 ml of dichloromethane and 10 ml of anisole at -5 ° C under argon are treated with 50 ml of trifluoroacetic acid by Kyle. P for 10 min. After stirring for 2.5 hours at a temperature of
    The mixture was diluted with 50 ml of ethyl acetate and filtered. The solid is washed with dichloromethane and then with ethyl acetate and dried to give 9.4 g of the title compound as a white granular solid.
    J. Diphenylmethyl ester (i) - (7.) - 2-1 - (2-amino-4-thiazolyl) -2 -2, 4-dimethyl-2-oxo-1- (sulfoxy) -3 -azetidin1-amino1 -2-oxo-tGs
    lidine amino -oxy -2-acrylic acid.
     to a solution of 2-amino-cb- (diphenylmethoxy) carbonyl vinsch-hydroxy-imino-4-thiao-acetic acid (167 g, 0.4 mmol) and triethylamine (56 μl, 1.0 g-eq.) under argon diphenylchlorophosphate (107 mg) is added at -30 ° C.
    0.4 mmol). The reaction mixture was stirred at -ZO C for 1 h with the formation of the mixed anhydride. (4) -3-Amino-A, D-dimethyl-2-o-co-1-β-ozetidinylsulfate (126 mg, 0.6 mmol) is dissolved in dimethylformamide at O C, this solution and triethylamine (71 μl, 0.85 g -eq.) are simultaneously added to the mixed anhydride solution at -30 ° C. The reaction mixture is stirred for 0.5 hours at -30 ° C and then slowly heated to 0 ° C in 1 hour. The reaction mixture is concentrated in vacuo, remaining in the mixture acetone / water, and adjust to pH 6.5 with 1 and. potassium bicarbonate solution. The mixture is then passed through a Dowex AG50 (K) column, eluted with 30% acetone / water. The appropriate fractions are combined and concentrated, and the residual aqueous solution is exposed to an HP20 column. The column was eluted with water and then an acetone / water gradient (0-100%). The appropriate fractions are combined and lyophilized to give the title compound, which is fully used in the next step.
    K. (h -) - (Z) -2- 1 - (2-Amino-4-thiazolyl) -2-4, 4-dimethyl-2-oxo-1 - - (sulfonic) -3-azethidinylJ aMHHoj -2-oxoethylidene-amino hydroxy -2-acrylic acid.
    In a flask containing (+) - (Z) - (2-amino-4-thiazolyl) diphenylmethyl ester, 4-dimethyl-2-OXO-1- (sulfoxy) -3-azetidinyl amino - 2-hydroxyethyl amine hydroxide -2-acrylic acid, methylene chloride (10 ml) and anisole (10 ml) are added. After cooling to-5 ° C, trifluoroacetic acid (8 ml) and the reaction mixture of methane are added.
    It is heated at -5 to 0 ° C. under argon for 45 minutes. Toluene is added and the reaction mixture is evaporated to a residue. Water and hexane are added to it and the layers are separated. The aqueous layer is adjusted to pH 2.5 with 10% potassium bicarbonate solution. An HP20 column was used, eluting first with water, then with an acetone / water gradient. The appropriate fractions were combined and lyophilized to afford the title compound as a white solid.
     (1: 1) Dj.O / CD, CN ,: J: 1.57 (s, ZN), 1.75 (s, ZN), 5.09 (s, 1H),
    0
    five
    0
    five
    0
    five
    0
    five
    five
    5.75 (d, I 2.3 Hz, 1H), 5.86 (d, I 2.3 Hz, 1H), 7.42 (s, 1H).
    Example 2. 3S (Z) - (2-Amino-4-thiazolyl) -2- (4,4-dimethyl-2-oxo-1- (sulfoxy) -3-azetidinylZamino -2-oxoethylidene-amino 1- -oxy -2-acrylic acid.
    A. 2- (1,3-dioxo-2H-isoindol--2-yl) -oxy-2-acrylic acid.
    A solution of t-butyl 2-f (l, 3-dioxo-2H-isoindol-2-yl) hydroxy -2-acrylic acid (49.9 g, 0.173 mol) in methylene chloride (300 ml) and anisole (150 ml) is treated with trifluoroacetic acid (300 ml). After stirring overnight at room temperature, 800 ml of dry toluene was added and the reaction mixture was concentrated in vacuo. The residue is triturated twice with hexane to give 39.6 g of the title compound „
    In Diphenylmethyl 2- (1, 3-DIOXO-2H-IZOINDOL-2-IL) oxy-2-acrylic acid.
    2- (1,3-dioxo-2H-isoindol-2-yl) oxy-2-acrylic acid (39.6 g, 0.17 mol) is dissolved in 800 ml of acetonitrile and at 0 ° C for 3 hours a solution of diphenyldiazomethane (43.4 g, 0.224 mol / 1000 ml acetonitrile) is added dropwise. The reaction solution is evaporated to a solid residue, which is triturated with hexane. The resulting solid is dissolved in dichloromethane and filtered through a pad of silica gel (Kiesel-, gel 60). Addition of hexane afforded 47.7 g of the title compound.
    C. 2-Amino-oi-LLLL (diphenylmethoxy) carbonyl vinyl oxyl-imino-4- -thiazo-acetic acid.
    To a solution of diphenylmethyl ester-2- | (1,3-dioxo-2H-iso-indol-2-yl) hydroxy -2-acrylic acid (6.07 g, 15.2 mmol) in 375 ml of methylene chloride under hydrazine hydrate (0.76 g, 15.2 mmol) in 4 MP absolute ethanol was added with argon at 0 ° C. After stirring for 1 hour at 0 ° C, the mixture is evaporated to dryness and is triturated with ethyl ether. Filtration and concentration of filtrates yields 2-amino-hydroxy-2-acrylic acid diphenylmethyl ester as a residue. This compound is treated at 20 ° C with a solution of 2-ami-i-o-4-thiazolglyoxylic acid (2.61 g, 15.2 mmol) in dimethylformamide (50 ml), followed by treatment with 5 ml of water. The reaction mixture was stirred at 20 ° C for 20 hours and then cooled and diluted with 250 m of water. Stirring the resulting gum gives a granular solid, which is filtered, washed with water and then azeotroped with acetonitrile to dryness. The dry solid is suspended with 100 ml of acetonitrile, filtered and finally washed successively with acetonitrile, ethyl ether and hexane. Drying on BO3j: yxe yields 1.97 g of the title compound.
    D. "..- MS-tilbenzylamine salt
    N- (t-j% of thyloxycarbonyl) -, - 3-oxivalen.
    Nt-butyloxycarbonyl-B, b-3 o ssivaline (7.02 g, 30 mmol) and 5 ml of ethyl ether are treated with 3.63 g (30 mmol) of S - (-) - "-methyl benzyl-amip . After 8 hours, the obtained solid is filtered. When recrypting from acetonitrile, 5, B g of the indicated 5 compound are obtained; m.p. 1A6 -, - -, j ° (C 2.0, methanol).
    E.N- (t-butyloxycarbonyl) -b-3-oxivgi1ii.
    A mixture of 204.6 g (0.577 mol) of the L- (t-butyl-hydroxycaronyl) -b-3-oxyalivine tylbenzylamine salt, ethyl neonate (3 l) of a solution of 100 g of potassium bisulfate and 150 g of sodium chloride in 1 l of water is shaken the layers are separated and the organic phase is washed with water and dried over magnesium sulfate. The concentration of the organic solution and trituration with 800 ml of hexane result in 136 g of the title compound; m.p. 120 - 121 ° C, oi, .p - + 7.81 °.
    F.K- (t-butyloxycarbonyl) -H - - (phenylmethoxy) -l-3-oxyalineamido
    Following the procedure of Example 1 (part I), but replacing L- (t-butyloxycarbonyl) -B, L-3-oxalivine N- (t-butyloxycarbonyl) -l-3-okoivaline, the title compound is obtained.
    G. (3S) -3- (t-butyloxycarbonyl) amino-4,4-dimethyl-1- (phenylmethoxy) -2 -2 azetidinone.
    A solution of 2-methylpyridine (296 ml, 3.0 mol) in methyl isobutyl ketone (2700 ml) under argon at -78 is treated dropwise with chlorosulfonic acid (80 ml, 1.2 mol) for 30 minutes. After completion of the addition, the temperature of the mixture is adjusted to 25 ° C for 30 minutes and maintained at this level for an additional 30 minutes. L- (t-butyloxycarbonyl) -Y - (phenylmethoxy) - -L-3-oxyalivamide (338.4 g, 1.0 mol) was added to this suspension and stirring was continued for 2 hours. Methylisobutyl ketone (800 ml), 4 (1222 g, 4.0 mol) and water (2700 ml) are added to 5 of this mixture and the mixture is heated to 70 ° C. Under heating, to the mixture is added dropwise. m for 15 min. 2N solution of potassium hydroxide (1000 ml, 2 mol) and the mixture is heated for another 55 minutes. The layers are separated and the aqueous phase is extracted with 500 ml of methyl isobutyl ketone. The combined organic layers are cooled to 0 ° C, washed with 3 liters of cold 20% potassium bisulfate, 1 liter of ice water, and a solution of 50 g of sodium bicarbonate and 100 g of sodium chloride in 1 l of water. The organic layer is dried over sodium sulfate and concentrated in vacuo. The residue is crystallized from 1.75 liters of isopropyl ether to give 161 g of the title compound; m.p. 121 - 122 ° C; Sob3- -f 21.06 ° (C 2.55, ,,).
    N. (35) -3- (t-butyloxycarbonsh1) aminoZ-1-hydroxy-4,4-dimethyl-2-azeti-0 dinon.
    A solution of 14.77 g (0.0461 mol) (WN) -3- (t-butyloxycarbonyl) -amino-4,4-dimethyl-1- (phenylmethoxy) -2-azetidinone in 15 ml of ethanol and 5 85 ml of ethyl acetate is hydrogenated in the presence of 0.75 g of 5% palladium carbon as a catalyst for 1.5 hours at a pressure of 1 atm. Filter the reaction and concentrate it to a white solid. Recrystallization from ethyl acetate affords 8.82 g of the title compound; T. p 148 - 149 ° С, “ill, + 31 (, ethyl acetate).
    1. Tetrabutylammonium salt (38) -3- (t-butyloxycarbonyl) amino -4,4-dimethyl-2-oxo-1 -azetidinyl sulfate.
    Following the procedure of Example 1, but replacing (±) -3- (t-butyloxycarbonyl) amino -1-hydroxy-A, D-dimethyl w-2-azetidine with (3S) -3- (t-butyloxy carbonyl) amino -1-hydroxy-A, 4-dimethyl--2-azetidinone, get mentioned in the title compound in the form of foam „
    J. (35) -3-Amino-A, 4 dimethyl-2-oxo-1-azetidinyl sulfate.
    Following the procedure of Example 1 (part I), but replacing the tetrabutylammonium salt of () -3- (t-butyloxycarbonyl) amino -4,4-dimethyl-2-oxo--1-azeti, Zinylsulfate by the tetrabutylammonium salt ( 35) -3- (t-butyloxycarbonyl) amino-4,4-dimethyl-2-oxo--1-azetidinyl sulfate; the title compound, recrystallization of a small sample from ethanol / water, results in the title compound. in the form of a crystalline solid; t, pl. 140 - 142 C (d), W.p 74.8 ° (C 1, H, ()).
    K. Tetrabutylammonium salt of diphenylmethyl ester 38 (ZD 1 - (2-amino-4-thiazolyl) -2-Lt, 4-dimethyl-2-oxo-1 (sulfoxy) -3-azetidinyl amino -2-oxoethylidene amino - hydroxy -2-acrylic acid
    To a solution of 2-amino-o-C 1- (diphenylmethoxy) carbonyl vinyl-oxy-amino 3-4-thiazoleacetic acid (1.423 g, 3.36 mmol) and triethylamine (0.404 g, 3.88 mmol) under argon at - Diphenylchlorophosphate (0.902 g, 3.36 mmol) is added at 30 ° C. The reaction mixture was stirred at -30 ° C for 1 hour to form a mixed leg of (35) -2-amino-4,4-dimethyl-22-oxo-1-azetidinyl sulfate anhydride (0.706 g, 3.36 mmol), dissolved in 4 ml of dimethylformamide with and this solution and triethylamine (0.404 g, 3.88 mmol) are simultaneously added to the mixed anhydride solution at –30 ° C. The reaction mixture is slowly heated to 0 ° C in 1 hour. The reaction mixture is treated with triethylamine ( 0.338 g, 3.36 mmol) and then concentrated in vacuo. The residue is treated with water to obtain a gum, which is separated from the aqueous layer and washed with additional water. The gum is dissolved in 100 ml of methylene chloride and shaken with a solution of tetrabutylammonium acid sulfate (1.1 g, 3.36 mmol) in 30 ml
    0 5
    about
    , d 5
    0
    five
    water. The organic phase is separated and washed three times with water, dried in the presence of sodium sulfate and evaporated. are up to foam. This foam is dissolved in 30 ml of methylene chloride and diluted to 120 ml with ethyl acetate. The title compound crystallized to give 1.73 g of a white solid; m.p. 170 - 172 C.
    L. WL ((2-Amino-4-thiazolyl), 4-dimethyl-2-oxo-1 - - (cyphoxy) -3-azettidine JamoJ-2-oxoethylidene amino-oxy-2-acrylic acid
    The solution of tetrabutylammonium salt of diphenylmethyl ester 35 (7.) (2-amino-4-thiazolyl - -2- (4, 4-dimethyl-2-oxo-1 - (sulfoxy) -3-azetidinyl amino1-2-oxoethyl - DenZamino-oxy 3-acrylic acid (2.17 g, 2.54 mmol) in methylene chloride (24 ml) and anisole (1 ml) at –12 ° C is treated with trifluoroacetic acid (8 ml) and the reaction mixture is stirred under argon for 1 hour. The mixture is treated dropwise with 60 ml of ethyl acetate and the remaining suspension is stirred for 20 minutes and then filtered and washed with ethyl acetate and hexane. This substance is suspended in 50 ml of water at 20 ° C. The crystals are formed within a few minutes. After crystallization, the solution is filtered and the solid is washed with water and dried under vacuum to give 0.9 g of the title compound; mp 140-170 ° C , decomposition
    Example 3. (±) - (Z) -rCCl- (2- -Amino-4-thiazolyl) -2-oxo-2- 2-oxy-1- (sulfoxy) -1-azaspiro (3.3) hept- 3-yl amino ethylidene amino oxide | -2-acrylic acid.
    A. N- - (t-Butyloxycarbonyl) (1-hydroxy-cyclic, lobutyl) glycine benzyl ester.
    A solution of diisopropylamine (9.7 ml, 70 mmol) in 150 ml of dry tetrahydrofuran at -40 ° C under argon is treated with 39 ml (64.5 mmol) of 1.71 n. a solution of n-butyl in hexane, and the pale yellow solution was stirred at -40 ° C for 20 minutes. The solution is cooled to -78 ° C, after which a solution of 7.95 g (30 mmol) of K- (t-butoxycarbonyl) glycine benzyl ester in 30 ml of dry tetrahydrofuran is poured into it drop-wise within 5 minutes. to obtain a dark yellow solution and after 20 min - to a slight turbidity. After 0.5 h, a solution of 2.42 g (2.0 ml, 34.5 mmol) of cyclobutanone in 30 ml of tetrahydrofuran is added. The resulting yellow turbid mixture is stirred at -78 ° C for 15 minutes, then placed in an ice-water bath for 2 hours. At an internal temperature of - (1 hour), the solution becomes bright, and at a temperature of -15 ° C dark purple. It is stirred at 0 ° C for 0.5 h, then treated with 3.96 g (66 mmol) of glacial acetic acid in 15 ml of tetrahydrofuran with a cloudy, light yellow mixture. This mixture is poured into 500 ml of cold water and extracted twice with ethladate. The extracts are washed with 2% potassium bisulfate solution, 5% sodium bicarbonate solution and brine, dried (sodium sulfate) and evaporated to a viscous oil. Chromatography over 800 ml of L PS-1 in a mixture of hexane / ethyl acetate (2:) and compound of the product fraction (Rj 0.29) yields 7.8 g of product in the form of an oil.
    B.N- (t-Butoxycarbonyl) -o .- (1-oxycyclobutyl) glycine.
    N- (T-Cytoxycarbonyl) (1-hydroxycyclobutyl) glycine benzyl ester (7.8 g, 23.3 mmol) is hydrogenated at 1 atm in the presence of palladium carbon as a catalyst in 150 ml of absolute ethanol for 4 h at 25 ° C. The catalyst is filtered and the solvent is evaporated in vacuo. Benzene is added and the mixture is evaporated twice to obtain 5.0 g of product as a rigid foam.
    C.N- (Benzipoxy) (t-butoxycarbonyl) (1 -oxycyclobutyl) glycine amide.
    N- (t-butoxycarbonyl) (1-oxycyclobutyl) glycine (5.0 g, 20.4 mmol) is dissolved in 150 ml of dry tetrahydrofuran under argon. Hydroxyben zotriazole hydrate (3.12 g, 20.4 mmol) is added to the solution, which is then cooled to 0 ° C and treated with 4.20 g (20.4 mmol) of dicyclohexyl carbodiimide. After 1.75 hours, a solution of 0-benzylhydroxyl amine in 15 ml of tetrahydrofuran is added at 0 ° C.
    the mixture is stirred at 0 - 25 ° C for 17 hours. The mixture of tetrahydrofuran is then cooled to - 10 ° C in 20 minutes and the resulting solids are filtered and washed with dry tetrahydrofuran. The filtrate is evaporated and the residue, taken up in ethyl acetate, is washed quickly with 2% potassium bisulfate, salt
    Q solution, 5% sodium bicarbonate and brine, then dried (sodium sulfate) and evaporated to a foam. Powder coating with isopropyl ether results in 4.69 g of product
    5 as a white solid; m.p. 95 - 97 s.
    D.1- (Benzyloxy) -Z- | (t-butyloxyxycarbonyl) amino-2-oxo-1-azaspiro (3.3) heptane.
    0 N- (Benzyloxy) -K - (t-butoxycarbonyl) .- (2-hydroxycyclobutyl) -glycine-amide (3.50 g, 10 mmol) in 200 ml of dry tetrahydrofuran is treated with 2.4 ml ( 15 mmol)
    5 diethyl azodicarboxylate, then a solution of triphenylphosphine (5.2 g, 20 mmol) in 50 ml of tetrahydrofuran for 10 min and the mixture is stirred at 0 ° C for 1 h. Remains
    The Q mixture is yellow so that an additional amount (0.52 g, 2 mmol) of triphenylphosphine is added. After 15 minutes, evaporation in vacuo gives an oil. Powdering with 100 ml of a mixture of hexane / ethyl acetate (2: 1) gives a white solid, which is filtered. Chromatography of the filtrate on 800 ml of LPS-1 results in fractions of the product (R 0.8 in a mixture of hexane / ethyl acetate, 1: 1) contaminated with dense impurity, which is removed by trituration of isopropyl :; lovy ether, to obtain the product as a white solid
    , (1.07 g), t. Pl. 156 - 157 C.
    E.Monatric salt of 3- (t-butoxycarbonyl) amino [-2-oxo-1- (sulfoxy) -asaspiro (3.3) heptane.
    1- (Benzyloxy) -3- (t-butoxycarbonyl) amino -2-oxo-1-azaspiro (3. 3) heptane (1.07 g, 3.22 mmol) is hydrogenated at 1 atm in 30 ml of absolute ethanol in the presence of 0.4 g of 10% pal0
    0
    l of di-carbon F as a catalyst for 3 hours at 25 ° C. The catalyst is filtered and the solvent is removed in vacuo at 10 ° C to obtain a solid residue. This solid residue taken in 19 ml of dry pyridium.
    15
    1.44 g (9 mmol) of the pyridine-trioxide complex compound is treated at 25 ° C under argon. After 4 hours, the volatile components were removed in vacuo, the residue was treated with water, and the pH was adjusted from 5.40 to 6.45% sodium hydroxide solution. Passing 40 ml of Dowex AC50 (K) in water in the water elutes pro-300 ml. Lyophilization results in a white solid, which is chromatographed on an HP-20 column first in water, then a gradient increase in acetone (20%). The product fractions lyophilized to obtain 0.75 g of product in shlp; - ;;; gptgp and: p.
    F. 3-Lmio-2-OKCo-l (sulfoxy) azaspiro (3.3) heptane.
    1on1) co: l 3- (t-butoxy-c; 1 rbonyl) amitkG -2 - oxo-1 - (sulfoxy) -1-lzaspiro (3.3) heptane (0.3 g, 0.87 p-th) are suspended in 2.5 ml of dry hydrochloric acid and 1.0 ml of anisole - 0 ° C under argon, and then the processing of D. oxyg ml of trifluoroacetic acid. After 0.5 h, a solid is formed. After 1.5 hours, 4 m of dry toluene is added and the mixture is evaporated in vacuo to give a solid, 3-l; (p.y - 3-oxo-1 - (sulfoxy) -1-lzaspiro (3.3) which is triturated in poroyutch twice with hexane and
    p gO
    dried in natguum at z3 C for
    1 hour
    G. Tetrabutylammonium salt of diphenylmethyl ester (1) - - (Z) (amino-4-thiazolyl) -2-oxo-2- 2-oxo-1- (sulfo si) - aza-spiro (3. 3 ) gent-3-ylJ aminoJ etching of amino oKciiJ-2-acrylic acid.
    Following the procedure of npnj iepa 2 (part K), but replacing (35) -3-amino-4,4 dimethyl-2-oxo-1-azetidinyl sulfate with compound 3-amino-2-oxo--1 - (sulfoxy) - 1-azaspiro (3.3) heptane, receive specified in the header of the connection.
    N. (±) - (Z) - (2-Amino-4-thiazolyl) -2 oxo-2-2-oxo-1- (sulfoxy) - -az spiro (3.3) hept-3-shlamino ethylidene amine oxy-J-2-acrylic acid,
    Following the procedure of Example 2 (part I), but there is tetrabutylammonium coj;), glozhnog (5S (X) diphenylmethyl ester (2) (2-amino-4-tnazolyl), 4-dimethyl 2-ca

    1776216
    co-1 - (sulfoxy) -3-azeT1schinyl 71 amine - -2-oxo-ethylidene-hydroxy-2-acryloxy acid with tetrabutylammonium salt compound (i:) - (Z) 1- (2--amino) -4-thiazolyl) -2-oxo-2-P2-oxo--1 - (sulfoxy) -1-azaspiro (3.3) hept-3-yl-amino-ethylidene amino oxy - Q -2-acrylic acid 1, and chromatographic precipitate from dissolving with ethyladetate on an HP-20 column (resin) instead of non-recrystallization from water,

    0
    five . l
    five
    0
    five
    Sully the title compound; m.p. 170-200 ° C, decomposition.
    The compounds of the present invention are active against gram-positive and gram-negative organisms and can be used as a means of controlling bacterial infections (including urinary tract infections and respiratory infections) in mammals, their species, such as, for example, domesticated animals (dogs, Kotki, cows, horses and the like) and people.
    To combat bacterial infections in mammals, the proposed compounds can be administered to a mammal in an amount of from 1.4 to 350 mg / kg / day, preferably from 14 to 100 mg / kg / day. All routes of administration that have been used for The availability of penicillins and defalosporins at the site of infection is also contemplated for use with the lactams of the invention. Such routes of administration include oral, intravenous, intramuscular, and in the form of suppositories with
    The compound of the present invention (indicated by SQ 31299) when tested for antibacterial activity was compared with a tigemonam of the formula
    CH-,
    OSO,
    where, when R is tigemona,
    with R - C - COOH - compound SO 31299.
    In addition, in the table, where the results of testing of new compounds for antibacterial activity are presented, the comparative data of the compounds of the invention with known antibiotics are given: amoxylin clavulanic acid (designated amox clav), cefaclor, cefixime, nerfloxalin, ofloxalin and trimethoprim sulfamethoxazole ( in the table - SXT with a corresponding ratio of 1:19 by weight).
    The minimum inhibitory concentration (MIC) in micrograms per 1 ml was determined by agar dilution. Antibiotics were obtained and diluted in agar medium by two-fold dilution. The bacterial inoculums are then placed on the surface of the agar using a multi-drop inoculum that supplies a known volume (Denley Instr. Or Mast SystemLtD). The plates are incubated at 37 ° C for 18-24 hours in an appropriate atmosphere.
    (Yeast-Beet) yeast agar (Difco) was used as an agar medium.
    n
    g
    N where H And Rj - lower alkyl or R
    and R, taken together - group () C,
    where R, to R; ji. have the indicated mean- 50phenylmethyl, phenylmen, thyl or tert-butyl,
    And, - the carboxyl-protecting group removes the carboxyl-protecting group, a group such as di-Bacterial inoculums was obtained by diluting the above-obtained Hje vecheon culture broth (Autibiotic Assay Broth :), BBo) or frozen stocks to certain titers. The strains of microorganisms were tested in I lO CF4 on a spot, the MIC for amox-clav (amoxylin:: clavulanic acid 1: 2 by weight) was defined as the concentrations of amoxy-silin. Accordingly, for trimethoprim sulfamethoxazole (SXT, 1:19 by weight trimethoprim: sulfamethoxazole), the MIC was defined as the concentration of sulfamethoxazole.
    SQ 31299 was also administered to animals for the determination of acute toxicity.
    At test concentrations, the compounds of the invention showed no signs of toxicity and could be classified as low-toxic compounds.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    The method of obtaining monosulfoctam General formula
    to,
    Ln
    . about 0-C-CCoH
    - / N,
    sn,
    about
    sn
    I
    ; C-N-OSOjH
    characterized in that a compound of the general formula
    SC, collection; the qualification of organisms was carried out in accordance with the collection of E.P.Sguibb and Lous Sguibb Prinecton, NY, USA.
    类似技术:
    公开号 | 公开日 | 专利标题
    DE3148021A1|1982-10-21|1-SULFO-2-OXOAZETIDINE DERIVATIVES, THEIR PRODUCTION AND THEIR USE
    CA1155444A|1983-10-18|Malonamidooxadethiacephem compounds
    DE2462736B1|1980-01-03|7-aminothiazolylacetamido-3-cephem-4-carboxylic acids and process for producing the same
    SU1517762A3|1989-10-23|Method of producing monosulfoctame
    HU198044B|1989-07-28|Process for production of 2-oxo-1-/|-/amin/-carbonil)-asetidines and medical preparatives containing these substances
    DE2529941A1|1976-04-08|AZETIDINONE DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION
    CS243499B2|1986-06-12|Method of new beta-lactams production
    SU1480763A3|1989-05-15|Method of producing derivatives of 1-surfo-2-oxoazetidinone or their salts or esters
    IE43845B1|1981-06-17|4-thia-1-azabicyclo/4.2.0/oct-2-ene derivatives
    CH669384A5|1989-03-15|
    US4166816A|1979-09-04|Methods and intermediates for preparing cis-4-oxoazetidine intermediates
    FI85022C|1992-02-25|Process for the Preparation of Therapeutically Useful / 3S | + - 2 - /// 1- | -2 - // 2,2-dimethyl-4-oxo-1- | - 3-azetidinyl / α mino / -2-oxoethylidene / amino / oxy / acetic acid
    DE2333256A1|1974-01-10|HALOGENPENAM AND HALOGENCEPHAM DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
    US4103086A|1978-07-25|8-Oxo-4-thia-1-azabicyclo |-oct-2-ene derivatives
    DE3035259A1|1981-03-19|CEPHALOSPORINE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
    KR840000500B1|1984-04-16|Process for penicillin epimerization
    US4229575A|1980-10-21|7-|-acetamido cephalosporin derivatives
    YOSHIDA et al.1985|STUDIES ON MONOCYCLIC β-LACTAM ANTIBIOTICS II. SYNTHESIS AND ANTIBACTERIAL ACTIVITY OF 3-ACYLAMINO-2-AZETIDINONE-1-OXYSULFONIC ACIDS
    EP0132395B1|1987-09-30|Improvements in or relating to the preparation of azetidinone sulfinic acids from cephalosporin sulfones
    CH618161A5|1980-07-15|Process for the preparation of azetidinone derivatives
    EP0066373B1|1985-03-20|Beta-lactam derivatives, a process for their preparation and compositions containing them
    Branch et al.1988|Direct incorporation of a 6α |-formamido group into penicillin and cephalosporin sulphides and sulphoxides
    US4341703A|1982-07-27|6-[D-α-|arylacetamido]-penicillanic acids or salts
    FI71562B|1986-10-10|FOERFARANDE FOER FRAMSTAELLNING AV 6-BETA-SUBSTITUERADE PENICILLANSYRA DERIVAT OCH SAOSOM MELLANPRODUKTER ANVAENDBARA 6-PERFLUORALKYLSULFONYLOXIPENICILLANSYRADERIVAT
    US4257947A|1981-03-24|3-Amino-2-hydroxy, halo or mercaptomethyl-4-oxoazetidines
    同族专利:
    公开号 | 公开日
    HU198926B|1989-12-28|
    DD267035A5|1989-04-19|
    YU127887A|1988-04-30|
    KR900002244B1|1990-04-07|
    AU5885190A|1990-10-25|
    AU5885090A|1990-11-15|
    AU602133B2|1990-10-04|
    NO166860C|1991-09-11|
    DD256700A5|1988-05-18|
    FI870030A|1987-07-07|
    ES2038127T3|1993-07-16|
    FI870030A0|1987-01-05|
    AU6680886A|1987-07-09|
    PH23052A|1989-03-10|
    IL81153D0|1987-08-31|
    ZA8771B|1987-08-26|
    AU617059B2|1991-11-14|
    GR3002312T3|1992-12-30|
    HUT44540A|1988-03-28|
    US4684722A|1987-08-04|
    DK3087D0|1987-01-05|
    AT64393T|1991-06-15|
    CA1308107C|1992-09-29|
    KR870007164A|1987-08-17|
    HU198700B|1989-11-28|
    DD267039A5|1989-04-19|
    IL81153A|1991-06-10|
    NZ218682A|1990-05-28|
    NO166860B|1991-06-03|
    DK3087A|1987-07-07|
    HUT48876A|1989-07-28|
    JPS62158278A|1987-07-14|
    EP0229012A1|1987-07-15|
    EP0229012B1|1991-06-12|
    NO870031D0|1987-01-05|
    DE3770644D1|1991-07-18|
    NO870031L|1987-07-07|
    YU227886A|1988-02-29|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    AU526540B2|1976-04-12|1983-01-20|Fujisawa Pharmaceutical Co., Ltd.|Oximes of substituted phenyl, thiazolyl - glyoxylic acids|
    DE2716677C2|1977-04-15|1985-10-10|Hoechst Ag, 6230 Frankfurt|Cephem derivatives and processes for their preparation|
    GB1602725A|1977-04-27|1981-11-18|Glaxo Operations Ltd|7--ceph-3-em-4-carboxylic acid derivatives|
    US4409214A|1979-11-19|1983-10-11|Fujisawa Pharmaceutical, Co., Ltd.|7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof|
    US4533660A|1980-10-31|1985-08-06|E. R. Squibb & Sons, Inc.|Antibacterial O-sulfated β-lactam hydroxamic acids|
    JPH0515692B2|1981-12-26|1993-03-02|Toyama Chemical Co Ltd|
    US4443374A|1982-02-01|1984-04-17|E. R. Squibb & Sons, Inc.|Process for preparing -3-[[[imino]-acetyl]amino]-2-oxo-1-azetidinesulfonic acid, and 4-substituted derivatives|
    AU564150B2|1982-04-30|1987-08-06|Takeda Chemical Industries Ltd.|1-sulfo-2-azetidinone derivatives|
    JPS58206589A|1982-05-26|1983-12-01|Yamanouchi Pharmaceut Co Ltd|2-azetidinone derivative|
    JPH0463066B2|1982-05-31|1992-10-08|Takeda Chemical Industries Ltd|
    CA1203806A|1982-05-31|1986-04-29|Susumu Nakagawa|2-oxo-1-azetidinesulfonic acid derivatives, processfor production thereof, and use thereof|
    DE3377061D1|1982-06-03|1988-07-21|Hoffmann La Roche|Process for the preparation of 1-sulfo-2-oxoazetidine derivatives|
    EP0096296B1|1982-06-03|1987-07-29|F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft|1-sulfo-2-oxoazetidine derivatives|
    US4704457A|1982-06-21|1987-11-03|E. R. Squibb & Sons, Inc.|Process for the preparation of -3-[[[2--4-thiazolyl]-oxoacetyl]amino]-2-oxo-1-azetidinesulfonic acid and 4-substituted derivatives thereof|
    GB8413152D0|1983-06-03|1984-06-27|Ici Pharma|Cephalosporin derivatives|
    DE3342929A1|1983-11-26|1985-06-05|Bayer Ag, 5090 Leverkusen|SS LACTAMANTIBIOTICS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS|JPS6452767A|1986-03-19|1989-02-28|Banyu Pharma Co Ltd|2--2-acetic acid derivative and production thereof|
    JPH0567158B2|1986-10-09|1993-09-24|Shinetsu Chem Ind Co|
    US5143913A|1988-04-04|1992-09-01|E. R. Squibb & Sons, Inc.|[3S]-3-[[[[2--2-oxoethoxy]imino]acetyl]amino]-2,2-dimethyl-4-oxo-1-azetidinyl sulfate|
    JPH07165740A|1994-11-07|1995-06-27|Banyu Pharmaceut Co Ltd|2--2-acetic acid and its production|
    CA2242877A1|1996-01-16|1997-07-24|Mark E. Duggan|Integrin receptor antagonists|
    US5952306A|1996-01-16|1999-09-14|Merck & Co., Inc.|Integrin receptor antagonists|
    US9120796B2|2013-10-02|2015-09-01|Cubist Pharmaceuticals, Inc.|B-lactamase inhibitor picoline salt|
    MX2018005382A|2015-12-15|2018-08-16|Merck Sharp & Dohme|Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections.|
    MX2018010878A|2016-03-07|2018-11-09|Merck Sharp & Dohme|Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections.|
    US10002721B1|2017-02-27|2018-06-19|Carling Technologies, Inc.|Multiple contact circuit breaker|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US06/816,475|US4684722A|1986-01-06|1986-01-06|Monosulfactams|
    [返回顶部]